daNIS-3: An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With Standard of Care (SOC) Anti-Cancer Therapy for the Second Line Treatment of Metastatic Colorect

Cancer Type

Metastases, Colorectal Cancer

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Sukeshi Arora MD

For more information about this study

View Details